Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis

NCT01016262 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

119

Enrollment

INDUSTRY

Sponsor class

Stopped The decision was taken solely for business/administrative reasons, no safety considerations entered into this. Ongoing randomized patients to complete.

Conditions

Proctitis, Ulcerative

Interventions

DRUG: MAX-002
DRUG: Placebo
DRUG: Canasa®

Sponsor

Forest Laboratories